TG Therapeutics, Inc. $TGTX Stock Holdings Increased by Citigroup Inc.

Citigroup Inc. lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 8.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 746,919 shares of the biopharmaceutical company’s stock after acquiring an additional 60,897 shares during the quarter. Citigroup Inc. owned 0.47% of TG Therapeutics worth $26,982,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TGTX. Public Sector Pension Investment Board lifted its holdings in TG Therapeutics by 14.5% in the third quarter. Public Sector Pension Investment Board now owns 529,271 shares of the biopharmaceutical company’s stock worth $19,120,000 after acquiring an additional 66,911 shares during the last quarter. Jump Financial LLC raised its position in shares of TG Therapeutics by 551.8% during the 2nd quarter. Jump Financial LLC now owns 320,022 shares of the biopharmaceutical company’s stock worth $11,518,000 after purchasing an additional 270,922 shares during the period. Marex Group plc acquired a new stake in shares of TG Therapeutics during the 2nd quarter worth approximately $10,017,000. Yorktown Management & Research Co Inc bought a new stake in shares of TG Therapeutics in the 2nd quarter worth approximately $383,000. Finally, Prudential Financial Inc. boosted its position in TG Therapeutics by 5.5% during the 2nd quarter. Prudential Financial Inc. now owns 189,315 shares of the biopharmaceutical company’s stock valued at $6,813,000 after purchasing an additional 9,925 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on TGTX shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a research report on Wednesday, January 14th. The Goldman Sachs Group lifted their price objective on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. reduced their target price on shares of TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Wall Street Zen cut TG Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Finally, Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

TG Therapeutics Price Performance

Shares of TGTX opened at $29.66 on Thursday. The company has a market capitalization of $4.71 billion, a price-to-earnings ratio of 10.67 and a beta of 1.85. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.82 and a quick ratio of 2.89. The business’s 50-day moving average is $29.85 and its 200-day moving average is $31.40. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.